Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.

Science. 1989 May 12;244(4905):707-12.

PMID:
2470152
2.

The role of the HER-2/neu oncogene in gynecologic cancers.

Cirisano FD, Karlan BY.

J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. Review.

PMID:
8796816
3.
4.

Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer.

Schwab M, Amler LC.

Genes Chromosomes Cancer. 1990 Jan;1(3):181-93. Review.

PMID:
1982063
5.

HER-2/neu signal transduction in human breast and ovarian cancer.

Reese DM, Slamon DJ.

Stem Cells. 1997;15(1):1-8. Review.

6.

Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.

Singleton TP, Strickler JG.

Pathol Annu. 1992;27 Pt 1:165-90. Review.

PMID:
1346551
7.

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.

Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ.

Am J Clin Pathol. 1999 Mar;111(3):311-6. Review.

PMID:
10078105
8.
9.

Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature.

Makar AP, Desmedt EJ, De Potter CR, Vanderheyden JS, Schatteman EA.

Acta Oncol. 1990;29(7):931-4. Review.

PMID:
1979748
10.

Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.

Meden H, Kuhn W.

Eur J Obstet Gynecol Reprod Biol. 1997 Feb;71(2):173-9. Review.

PMID:
9138962
11.

HER-2/neu oncogene amplification and expression in breast and ovarian cancers.

Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ.

Prog Clin Biol Res. 1990;354A:209-21. Review. No abstract available.

PMID:
1978943
12.

[DNA analysis of breast cancer].

Ohuchi N, Mori S.

Gan To Kagaku Ryoho. 1991 Jan;18(1):30-6. Review. Japanese.

PMID:
1987899
13.

[Genetic alterations in the genesis and development of ovarian cancer].

Okamoto A, Yokoyama S, Terashima Y.

Gan To Kagaku Ryoho. 1992 Oct;19(12):1971-6. Review. Japanese.

PMID:
1358031
14.

Neu (c-erbB-2), a tumor marker in carcinoma of the female breast.

Maguire HC Jr, Greene MI.

Pathobiology. 1990;58(6):297-303. Review.

PMID:
1981830
15.

[Current molecular prognostic factors in breast carcinoma].

Fey MF, Andres AC, Castiglione-Gertsch M.

Schweiz Med Wochenschr. 1992 Oct 3;122(40):1471-8. Review. German.

PMID:
1357743
16.

c-erbB-2 oncogene as a prognostic marker in breast cancer.

Perren TJ.

Br J Cancer. 1991 Mar;63(3):328-32. Review. No abstract available.

17.

Oncogenes in ovarian cancer.

Berchuck A, Kohler MF, Bast RC Jr.

Hematol Oncol Clin North Am. 1992 Aug;6(4):813-27. Review.

PMID:
1500387
18.

ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues.

Thor A, Ohuchi N, Hand PH, Callahan R, Weeks MO, Theillet C, Lidereau R, Escot C, Page DL, Vilasi V, et al.

Lab Invest. 1986 Dec;55(6):603-15. Review. No abstract available.

PMID:
2431221
19.

[Oncogenes and oncogene products--possibilities and significance of their detection].

Höfler H.

Verh Dtsch Ges Pathol. 1990;74:319-27. Review. German.

PMID:
1708608
20.

The genetics of ovarian cancer.

DiCioccio RA, Piver MS.

Cancer Invest. 1992;10(2):135-41. Review. No abstract available.

PMID:
1551023

Supplemental Content

Support Center